Intracellular Glucose-Depriving Polymer Micelles for Antiglycolytic Cancer Treatment

Adv Mater. 2023 Mar;35(10):e2207342. doi: 10.1002/adma.202207342. Epub 2023 Jan 25.

Abstract

A new anticancer strategy to exploit abnormal metabolism of cancer cells rather than to merely control the drug release or rearrange the tumor microenvironment is reported. An antiglycolytic amphiphilic polymer, designed considering the unique metabolism of cancer cells (Warburg effect) and aimed at the regulation of glucose metabolism, is synthesized through chemical conjugation between glycol chitosan (GC) and phenylboronic acid (PBA). GC-PBA derivatives form stable micellar structures under physiological conditions and respond to changes in glucose concentration. Once the micelles accumulate at the tumor site, intracellular glucose capture occurs, and the resultant energy deprivation through the inhibition of aerobic glycolysis remarkably suppresses tumor growth without significant side effects in vivo. This strategy highlights the need to develop safe and effective cancer treatment without the use of conventional anticancer drugs.

Keywords: apoptosis; cancer therapy; glucose-responsive polymers; induced energy deficiency; nutrient deprivation.

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Drug Carriers / chemistry
  • Drug Liberation
  • Glucose / metabolism
  • Humans
  • Micelles
  • Neoplasms* / drug therapy
  • Polymers / chemistry
  • Tumor Microenvironment

Substances

  • Micelles
  • Polymers
  • Glucose
  • Drug Carriers
  • Antineoplastic Agents